Looking Beyond Diabetes: The Role of SGLT2i and MRAs in Cardiorenal Disease

Looking Beyond Diabetes: The Role of SGLT2i and MRAs in Cardiorenal Disease is organized by ReachMD.

Release Date: 08/26/2022
Expiration Date: 08/26/2023

Overview:
Optimizing Gdmt for Patients With Heart Failure and Concomitant Kidney Dysfunction and/or Diabetes Continues to Be a Challenge Despite the Overwhelming Clinical Evidence and Recent Updates to the Guidelines for Heart Failure Management. Recent Evidence From Clinical Trials With Sglt2 Inhibitors and Mineralocorticoid Receptor Antagonists and the Use of Novel Potassium Binders Provide New Therapeutic Opportunities for These Patients. This Activity Will Review the Current Challenges in Initiating and Maintaining Patients on Optimal Raasi Therapy and Approaches to Improve Cardiorenal Outcomes.

Learning Objectives:
After participating in this educational activity, participants should be better able to:
• Describe the current challenges in optimizing RAASi therapy for patients with HFrEF and concomitant kidney dysfunction and/or diabetes
• Interpret evidence-based approaches to modification of RAASi therapy in patients with HFrEF and kidney dysfunction
• Evaluate the clinical evidence for use of SGLT2 inhibitors and MRAs in optimizing RAASi therapy in patients with HFrEF and concomitant diabetes and declining renal function